10-K: Acadia Pharmaceuticals Reports Strong 2025 Sales, Pipeline Advances Amid EU Regulatory Setback

Acadia Pharmaceuticals reported net product sales of $1.07 billion in 2025, driven by growth in NUPLAZID and DAYBUE, despite a negative trend vote for DAYBUE's EU approval.

Summary

• Net product sales for 2025 totaled $1,071.5 million, an increase from $957.8 million in 2024.
• NUPLAZID net sales grew to $680.1 million in 2025 from $609.4 million in 2024.
• DAYBUE net sales increased to $391.4 million in 2025 from $348.4 million in 2024.
• The company achieved cumulative three-year profitability, leading to a $340.4 million reduction in its deferred tax asset valuation allowance.
• The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote in January 2026 on the marketing authorization application (MAA) for trofinetide (DAYBUE) for Rett syndrome in the European Union.
• The FDA approved DAYBUE STIX, a new powder formulation for Rett syndrome, in December 2025, with a broader launch planned for Q2 2026.
• Development of ACP-101 for hyperphagia in Prader-Willi syndrome was discontinued in September 2025 after its Phase 3 COMPASS PWS study failed to meet primary and secondary endpoints.
• Phase 2 studies for remlifanserin in Alzheimer's disease psychosis (ADP) and Lewy Body Dementia Psychosis (LBDP) are ongoing, with the LBDP study initiated in September 2025.
• A Phase 2 study of ACP-211 for major depressive disorder (MDD) was initiated in Q4 2025.
• The company successfully defended NUPLAZID patent infringement cases against MSN and Aurobindo in June 2025, with appeals filed by the defendants.
• A settlement in principle was reached for a derivative suit in January 2026, including governance reforms and $1.5 million in attorneys' fees covered by insurance.
• A cyberattack on a prescription processor in February 2024 and a data security incident involving NUPLAZID patient data in April 2024 were disclosed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While commercial product sales show strong growth and the company achieved profitability, significant pipeline setbacks (ACP-101 failure, negative EU vote for DAYBUE) and ongoing legal/regulatory challenges temper the positive financial performance. The future outlook depends heavily on successful pipeline execution and navigating regulatory hurdles.

Positives

• Net product sales increased by 11.9% to $1,071.5 million in 2025, demonstrating strong commercial growth.
• NUPLAZID sales grew by $70.7 million to $680.1 million in 2025, indicating continued market penetration in Parkinson's disease psychosis.
• DAYBUE sales increased by $43.0 million to $391.4 million in 2025, reflecting strong adoption for Rett syndrome.
• Achieved cumulative three-year profitability, resulting in a significant $340.4 million reduction in the deferred tax asset valuation allowance.
• FDA approval of DAYBUE STIX in December 2025 provides a new, flexible formulation for Rett syndrome patients, potentially expanding market access.
• Health Canada granted marketing authorization for DAYBUE in October 2024, and the Ministry of Health in Israel approved DAYBUE in December 2025, expanding international reach.
• Advanced multiple pipeline candidates into Phase 2 studies, including remlifanserin for ADP and LBDP, and ACP-211 for MDD, indicating a robust development pipeline.
• Successfully affirmed District Court judgments in its favor in NUPLAZID patent infringement cases against MSN and Aurobindo in June 2025.
• Reached a settlement in principle for a derivative suit, including governance reforms and attorneys' fees covered by insurance, mitigating potential litigation costs and risks.
• Maintained a strong cash, cash equivalents, and investment securities balance of $819.7 million at December 31, 2025.

Negatives

• The EMA's CHMP issued a negative trend vote in January 2026 on the MAA for trofinetide (DAYBUE) in the EU, posing a significant hurdle to international expansion.
• Discontinued development of ACP-101 for Prader-Willi syndrome in September 2025 after its Phase 3 study failed to meet endpoints.
• Pimavanserin failed to meet primary endpoints in a Phase 3 study for negative symptoms of schizophrenia (March 2024) and a Phase 2 trial for irritability associated with autism spectrum disorder (October 2024), leading to discontinuation of further exploration in these indications.
• An unfavorable gross-to-net adjustment of approximately $20.1 million was recorded for Medicare inflation cap rebates related to NUPLAZID sales from October 1, 2022, to December 31, 2025.
• Research and development expenses increased to $328.8 million in 2025 from $303.2 million in 2024.
• Selling, general and administrative expenses increased to $548.9 million in 2025 from $488.4 million in 2024.
• A cyberattack on a prescription processor in February 2024 impacted the ability of specialty pharmacy partners to obtain payor authorizations for product refills and new patient starts.
• A data security incident in April 2024 involved personal data of NUPLAZID patients.
• Ongoing securities class action and opt-out litigation related to prior statements about NUPLAZID's sNDA for dementia-related psychosis continue to pose legal and financial risks.

Risks

• Prospects are highly dependent on the successful commercialization of NUPLAZID and DAYBUE; inability to maintain or increase sales could materially adversely affect business.
• Products may not gain maximal acceptance among physicians, patients, caregivers, and the medical community, thereby limiting revenue potential.
• Ability to generate product revenues will be diminished if coverage from commercial or government payors is not provided, is decreased, or if patients have unacceptably high out-of-pocket requirements.
• Products are subject to ongoing regulatory requirements that could cause significant expense and delay or limit sales revenues.
• Reliance on a limited network of third-party distributors and pharmacies; if this approach ceases to be effective, commercialization may be adversely affected.
• Drug development is a long, expensive, and unpredictable process with a high risk of failure; no guarantee product candidates will be successful or obtain regulatory approval.
• Regulatory approval processes outside North America (e.g., EU) are lengthy, time-consuming, and unpredictable; failure to obtain approval for trofinetide outside North America will limit commercial revenues.
• Expanded access or compassionate use programs could subject the company to additional risks, including serious adverse events impacting the safety profile.
• Delays, suspensions, variations, and terminations in clinical trials for product candidates could result in increased costs and delay revenue generation.
• Inability to attract, retain, and motivate key management, research and development, and sales and marketing personnel could delay drug development and commercialization plans.
• Failure to develop, acquire, or in-license other product candidates or products would limit business and prospects.
• May require additional financing in the future; inability to raise funds could prevent funding business plans and future efforts.
• Operating results are expected to fluctuate, making future performance difficult to predict.
• Changes in tax laws or regulations could adversely affect business, cash flow, financial condition, or results of operations.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes.
• Tax authorities could reallocate taxable income among subsidiaries, increasing overall tax liability.
• Unfavorable global economic conditions could adversely affect business, financial condition, or results of operations.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business.
• Adverse effects from catastrophic events (e.g., natural disasters) on the company or third parties.
• Significant costs from laws, regulations, and standards related to corporate governance, workforce initiatives; failure to comply could adversely affect business.
• Business involves hazardous materials; compliance with environmental, health, and safety laws can be expensive and restrict operations.
• Dependence on collaborations with third parties to develop product candidates; collaborators may fail to perform.
• Conflicts or disputes in collaborations could harm business, reputation, and financial condition.
• Reliance on third parties to conduct clinical trials and perform data collection/analysis, leading to potential costs and delays.
• Dependence on third parties to manufacture products and product candidates; failure to provide adequate supplies or comply with regulations could impede development/commercialization.
• Inability to continue or fully exploit collaborations with outside scientific and clinical advisors could impair progress.
• Ability to compete may decline if proprietary rights are not adequately protected, facing generic competition.
• Disputes concerning infringement or misappropriation of proprietary rights could be costly and time-consuming.
• Uncertainty in patent strength in pharmaceutical/biotechnology fields; patents may be challenged, invalidated, or circumvented.
• Confidentiality agreements may not adequately prevent disclosure of trade secrets.
• Healthcare reform measures may negatively impact ability to sell products profitably.
• Subject to federal, state, and foreign healthcare laws and regulations (fraud, abuse, transparency, privacy); non-compliance could lead to substantial penalties.
• Stringent and evolving data privacy and security laws; actual or perceived failure to comply could lead to investigations, litigation, fines, and business disruptions.
• Failure to comply with Medicaid Drug Rebate Program or other governmental pricing programs could lead to additional reimbursement requirements, fines, and sanctions.
• Liability if a regulatory authority determines that the company is promoting its products for any off-label uses.
• Changes at the FDA and other government agencies could delay or prevent new products from being developed or commercialized in a timely manner.
• Competitors developing and marketing products that are more effective than current products may reduce or eliminate commercial opportunity.
• Product liability lawsuits could incur substantial liabilities and may require limiting commercialization of products or product candidates.
• Information technology systems or data, or those of third parties with whom the company works, being compromised could lead to adverse consequences.
• Stock price historically has been, and is likely to remain, highly volatile.
• Sales of substantial amounts of common stock by officers, directors, and largest stockholders could cause the market price of common stock to decline.
• Anti-takeover provisions in charter documents and under Delaware law may make an acquisition of the company more complicated and may make the removal and replacement of directors and management more difficult.
• The exclusive forum provision in the bylaws could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• No intention to pay dividends on common stock in the foreseeable future; investors must rely on stock appreciation for any return.

Future Outlook

The company aims to achieve $1.0 billion in NUPLAZID net sales by 2028 and expects DAYBUE sales growth to be driven by new patient adoption and the Q2 2026 broader launch of DAYBUE STIX. Enrollment in the Phase 2 RADIANT study for remlifanserin (ADP) is expected to complete in H1 2026, with top-line results anticipated in August to October 2026. A Phase 2 study of ACP-711 for essential tremor is planned for Q4 2026 or Q1 2027, and a Phase 1 study for ACP-271 is planned for Q1 2026. Top-line results from the Japan Phase 3 trofinetide trial are expected in Q4 2026 or Q1 2027. The company anticipates increased research and development expenses as early-stage product candidates advance and expects current financial resources and anticipated sales to fund operations beyond the next 12 months. The overall cost of product sales as a percentage of net product sales is estimated to be in the mid-single digit to high single digit range after depleting zero-cost inventories.

Management Comments

• "Our strategy is to build a strong foundation for growth with multiple innovative commercial products and product candidates that address high unmet medical needs and have the potential to be impactful products in our core franchises of neurological and rare diseases, including adjacencies within rare disease."
• "We believe that with an approximate 25% current market share of the 130,000 Parkinsons disease patients that are treated with an atypical antipsychotic annually in the United States, we have ample opportunity to grow sales of NUPLAZID while delivering increasing annual cash flow to reinvest in overall corporate growth."
• "Based on the number of Rett syndrome patients in the U.S., we believe there remains a substantial opportunity for new patient adoption."
• "We expect that our cash, cash equivalents and investment securities, as well as funds generated by anticipated sales of our products, will be sufficient to fund our planned operations through and beyond the next 12 months."
• "We currently believe that none of the foregoing claims or other actions pending against us as of December 31, 2025 is likely to have, individually or in the aggregate, a material adverse effect on our business, liquidity, financial position, or results of operations."

Industry Context

StockSavvy.ai notes that Acadia Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on neurological and rare diseases. The company's strategy to maximize growth of existing commercial products like NUPLAZID (the only FDA-approved drug for PDP) and DAYBUE (the first and only approved drug for Rett syndrome) aligns with industry trends of leveraging established assets. However, the challenges in expanding DAYBUE into the EU, as evidenced by the negative trend vote from the EMA's CHMP, highlight the significant regulatory hurdles and market access complexities faced by pharmaceutical companies globally. The discontinuation of ACP-101 for Prader-Willi syndrome underscores the high failure rate inherent in drug development, even in late-stage trials. The company's investment in precision medicine, data innovation (AI/ML), globalization, and patient empowerment reflects broader industry shifts towards more targeted therapies, digital transformation, and patient-centric development. The ongoing patent litigation and the impact of healthcare reform measures, such as the OBBBA and Medicare Drug Price Negotiation Program, are common industry-wide pressures affecting profitability and market strategies.

Comparison to Industry Standards

• The filing mentions competition from off-label use of various antipsychotic drugs (quetiapine, clozapine, risperidone, aripiprazole, olanzapine) for NUPLAZID in PDP, and branded/generic medications for individual symptoms of Rett syndrome for DAYBUE.
• For Rett syndrome, specific competitors and their pipeline programs are noted: UCB S.A. (fenfluramine Phase 3), Taysha Gene Therapies (AAV9 intrathecal gene therapy pivotal trial), Neurogene (NGN-401 gene therapy pivotal trial), and Unravel Bio/Vanderbilt University Medical Center (vorinostat early-stage study).
• The company acknowledges that many competitors have significantly greater experience and advantages in capital resources, R&D, manufacturing, and sales/marketing, which is a common competitive landscape in the biopharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• **Patent Infringement (NUPLAZID):** The company filed complaints against multiple generic drug manufacturers (Aurobindo, Teva, Hetero, MSN, Zydus) alleging infringement of NUPLAZID patents. Settlements were reached with Hetero (allowing generic launch Feb 27, 2038) and Zydus (allowing generic 10mg tablet launch Sept 23, 2036, and 34mg capsule launch Feb 27, 2038). The company won against MSN in the Pimavanserin I Case (affirmed by Federal Circuit June 9, 2025) and against Aurobindo in the Pimavanserin II Case (District Court judgment June 9, 2025, appealed by MSN and Aurobindo). A new complaint was filed against Zydus in February 2025 for a proposed 34mg pimavanserin tablet, with trial scheduled for November 2, 2026.
• **Securities Class Action:** A putative securities class action (City of Birmingham Relief Retirement Systems v. Acadia Pharmaceuticals, Inc.) was filed in April 2021, alleging violations of federal securities laws for failing to disclose deficiencies in the sNDA for pimavanserin for dementia-related psychosis. Class certification was granted in March 2024, discovery concluded in September 2025, and a pretrial motions hearing is scheduled for April 10, 2026.
• **Opt-Out Litigation:** An opt-out litigation (Alger Dynamic Opportunities Fund v. Acadia Pharmaceuticals, Inc.) was filed in March 2024, based on similar allegations as the securities class action. The suit was stayed in January 2025 pending the outcome of the securities class action.
• **Derivative Suit:** A derivative action (Kanner et al v. Biggar et al.) was filed in December 2023, asserting state and federal claims against certain directors based on alleged misconduct similar to the securities class action. A settlement in principle was reached in January 2026, subject to court approval, including governance reforms and $1.5 million in attorneys' fees paid by the company's insurance carrier.
• The company believes that none of these claims are likely to have a material adverse effect on its business, liquidity, financial position, or results of operations as of December 31, 2025, but cannot predict the outcome of these matters.

Related Party Transactions

• The company entered into a new registration rights agreement on February 24, 2026, with 667, L.P. and Baker Brothers Life Sciences, L.P. (the Baker Entities), which are existing stockholders affiliated with directors Julian C. Baker and Stephen R. Biggar. This agreement covers all securities held or later acquired by the Baker Entities and includes obligations to facilitate underwritten public offerings and block trades for up to 10 years.

Stakeholder Impact

• **Shareholders:** Experience potential stock price volatility due to clinical trial results, regulatory decisions (e.g., EU DAYBUE), ongoing legal proceedings, and potential sales of common stock by large holders. Positive financial performance and pipeline advancements could benefit shareholders, but future financing could lead to dilution.
• **Patients/Caregivers:** Benefit from the continued availability of NUPLAZID and DAYBUE, and the potential for new treatment options from pipeline candidates (remlifanserin, ACP-211, ACP-711, ACP-271). The approval of DAYBUE STIX offers improved administration for Rett syndrome patients. The discontinuation of ACP-101 means no new treatment for Prader-Willi syndrome from the company.
• **Employees:** Benefit from competitive compensation, equity opportunities, comprehensive benefits, and investment in professional development. The company's focus on Diversity, Equity, Inclusion & Belonging (DEIB) aims to foster a positive workplace culture. Success in product development and commercialization impacts job security and growth opportunities.
• **Customers (Specialty Pharmacies/Distributors):** Continue to operate within a limited network for product distribution. Their operations can be impacted by product availability, pricing changes, and regulatory requirements. Recent cyberattacks on prescription processors have affected their ability to secure payor authorizations.
• **Regulatory Authorities:** Engage in ongoing review and approval processes for products and facilities, post-marketing requirements, and inspections, influencing market access and product lifecycle.
• **Suppliers/Manufacturers:** The company relies heavily on a network of third-party manufacturers. They face potential supply chain disruptions due to geopolitical and macroeconomic factors, including tariffs, which could impact their ability to produce and deliver products.

Next Steps

• Request a re-examination of the EMA's CHMP negative trend vote for trofinetide (DAYBUE) MAA in the EU, with an opinion expected in February 2026.
• Prepare for a potential launch of trofinetide in the EU in Q3 2026, anticipating potential approval.
• Complete enrollment in the Phase 2 RADIANT study of remlifanserin for ADP in the first half of 2026.
• Report top-line results from the Phase 2 RADIANT study in August to October 2026.
• Initiate a Phase 2 study of ACP-711 in essential tremor in Q4 2026 or Q1 2027.
• Initiate a Phase 1 study for ACP-271 (tardive dyskinesia and Huntington's disease) in Q1 2026.
• Report top-line results from the Japan Phase 3 trofinetide trial in Q4 2026 or Q1 2027.
• Conduct a broader launch of DAYBUE STIX powder for oral solution in Q2 2026.
• Continue to increase NUPLAZID field force size and efficiency, leverage real-world evidence, and activate consumers with direct-to-consumer campaigns.
• Drive new patient adoption for DAYBUE, optimize patient experience, increase field force size/efficiency, continue direct-to-consumer campaigns, and deploy an omni-channel strategy.
• Continue to develop early-stage product candidates and pursue strategic business development opportunities.
• Continue to invest in precision medicine, data innovation (AI/ML), globalization, and patient empowerment capabilities.
• Proceed with the trial scheduled for November 2, 2026, for the Zydus NUPLAZID patent infringement case.
• Attend the pretrial motions hearing for the securities class action scheduled for April 10, 2026.
• Expect to receive an invoice for Medicare inflation cap rebates for the period of October 1, 2024, to September 30, 2025, in June 2026.

Key Dates

Recommendation

Acadia Pharmaceuticals demonstrates strong commercial performance with NUPLAZID and DAYBUE, achieving profitability and advancing its pipeline. However, the negative trend vote for DAYBUE's EU approval and the discontinuation of ACP-101 for PWS introduce significant uncertainty and risk to future growth. While the company has a robust cash position and positive legal outcomes in patent cases, the ongoing securities litigation and potential for further regulatory hurdles warrant a cautious 'hold' stance until there is greater clarity on DAYBUE's international expansion and the success of its late-stage pipeline.

Keywords

Biopharmaceutical, Neurology, Rare Disease, Parkinson's Disease Psychosis, Rett Syndrome, NUPLAZID, DAYBUE, Pimavanserin, Trofinetide, Remlifanserin, Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis, Major Depressive Disorder, Essential Tremor, Tardive Dyskinesia, Huntington's Disease, SEC Filing, 10-K, Financial Results, Clinical Trials, Regulatory Approval, Patent Infringement, Corporate Governance, Risk Factors, Pipeline, Commercialization